Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 211Rn/211At and 209At production with intense mass separated Fr ion beams for preclinical 211At-based α-therapy research.

Literature DB >> 28189025

²¹¹Rn/²¹¹At and ²⁰⁹At production with intense mass separated Fr ion beams for preclinical ²¹¹At-based α-therapy research.

Jason R Crawford¹, Peter Kunz², Hua Yang², Paul Schaffer², Thomas J Ruth¹.

Abstract

Mass-separated francium beams (211Fr or 213Fr) were implanted into solid targets for producing 211Rn (14.6h half-life) or 209At (5.41h), in situ. 211Rn was transferred to dodecane and isolated from contaminants, providing sources for 211At (7.21h) production by 211Rn decay (73%). 209At was recovered with high radionuclidic purity in aqueous solutions, directly. These experiments demonstrated Fr beam implantations as a novel method for producing preclinical quantities of 211Rn/211At (for therapy) and 209At (for imaging).

Entities: Chemical

Keywords: At-209; At-211; ISOL-technique, rare isotope beam; astatine-209; astatine-211; francium; generator system; ion implantation; radioisotope production; radon-211; targeted alpha therapy

Mesh：

Substances：

Year: 2017 PMID： 28189025 DOI： 10.1016/j.apradiso.2017.01.035

Source DB: PubMed Journal: Appl Radiat Isot ISSN： 0969-8043 Impact factor: 1.513

Keyword Cloud
Cited

3 in total

Review 1. Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure.

Authors: Sture Lindegren; Per Albertsson; Tom Bäck; Holger Jensen; Stig Palm; Emma Aneheim
Journal: Cancer Biother Radiopharm Date: 2020-02-20 Impact factor: 3.099

Review 2. Production, purification and availability of ²¹¹At: Near term steps towards global access.

Authors: Yutian Feng; Michael R Zalutsky
Journal: Nucl Med Biol Date: 2021-06-10 Impact factor: 2.947

3. Evaluation of polydentate picolinic acid chelating ligands and an α-melanocyte-stimulating hormone derivative for targeted alpha therapy using ISOL-produced ²²⁵Ac.

Authors: Caterina F Ramogida; Andrew K H Robertson; Una Jermilova; Chengcheng Zhang; Hua Yang; Peter Kunz; Jens Lassen; Ivica Bratanovic; Victoria Brown; Lily Southcott; Cristina Rodríguez-Rodríguez; Valery Radchenko; François Bénard; Chris Orvig; Paul Schaffer
Journal: EJNMMI Radiopharm Chem Date: 2019-08-06

3 in total

211Rn/211At and 209At production with intense mass separated Fr ion beams for preclinical 211At-based α-therapy research.

Review 1. Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure.

Review 2. Production, purification and availability of 211At: Near term steps towards global access.

3. Evaluation of polydentate picolinic acid chelating ligands and an α-melanocyte-stimulating hormone derivative for targeted alpha therapy using ISOL-produced 225Ac.

²¹¹Rn/²¹¹At and ²⁰⁹At production with intense mass separated Fr ion beams for preclinical ²¹¹At-based α-therapy research.

Review 2. Production, purification and availability of ²¹¹At: Near term steps towards global access.

3. Evaluation of polydentate picolinic acid chelating ligands and an α-melanocyte-stimulating hormone derivative for targeted alpha therapy using ISOL-produced ²²⁵Ac.